Investment analysts at HC Wainwright began coverage on shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) in a research note issued to investors on Tuesday. The firm set a “buy” rating and a $66.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 71.07% from the stock’s current price.

Several other research analysts have also recently weighed in on AERI. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $20.00 price target for the company in a report on Monday, July 4th. Stifel Nicolaus increased their target price on shares of Aerie Pharmaceuticals from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 15th. Cantor Fitzgerald started coverage on shares of Aerie Pharmaceuticals in a report on Thursday, June 2nd. They set a “buy” rating and a $44.00 target price for the company. Royal Bank Of Canada increased their target price on shares of Aerie Pharmaceuticals from $51.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, September 15th. Finally, Brean Capital set a $48.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, September 15th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Aerie Pharmaceuticals has a consensus rating of “Buy” and an average target price of $49.40.

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ:AERI) traded up 13.07% during mid-day trading on Tuesday, reaching $38.58. 4,350,122 shares of the company’s stock traded hands. The firm’s market cap is $1.08 billion. The firm has a 50 day moving average of $20.94 and a 200 day moving average of $17.12. Aerie Pharmaceuticals has a 1-year low of $10.82 and a 1-year high of $38.98.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/aerie-pharmaceuticals-inc-aeri-earns-buy-rating-from-analysts-at-hc-wainwright.html

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. Analysts forecast that Aerie Pharmaceuticals will post ($2.77) EPS for the current year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. purchased 250,000 shares of the company’s stock in a transaction on Friday, July 22nd. The shares were purchased at an average cost of $17.50 per share, with a total value of $4,375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 8.77% of the company’s stock.

A number of hedge funds have recently bought and sold shares of AERI. Schwab Charles Investment Management Inc. raised its stake in Aerie Pharmaceuticals by 25.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 37,544 shares of the company’s stock valued at $661,000 after buying an additional 7,700 shares during the period. Metropolitan Life Insurance Co. NY raised its stake in Aerie Pharmaceuticals by 16.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,893 shares of the company’s stock valued at $315,000 after buying an additional 2,544 shares during the period. Iguana Healthcare Management LLC raised its position in shares of Aerie Pharmaceuticals by 100.0% in the second quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the company’s stock valued at $2,640,000 after buying an additional 75,000 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Aerie Pharmaceuticals by 3.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock valued at $36,960,000 after buying an additional 75,000 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock valued at $106,000 after buying an additional 200 shares during the last quarter. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.